Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis.
BACKGROUND
Despite supplementation with standard multivitamins and pancreatic enzymes, deficiencies of vitamins D and K and antioxidants are common in cystic fibrosis (CF).


METHODS
In this non-randomized, open-label study, AquADEKs® softgels were given daily over 12 weeks to 14 CF subjects (mean age 15 years, range 10-23) without a preceding wash-out period. Both pancreatic sufficient and insufficient subjects were enrolled. Plasma vitamin and antioxidant levels, urine 8-isoprostane levels, anthropometric measures, and pulmonary function were determined at baseline, 6 and 12 weeks.


RESULTS
Daily supplementation significantly increased plasma beta(β)-carotene, coenzyme Q10, and γ-tocopherol concentrations, decreased proteins induced in vitamin K absence (PIVKA-II) levels, but did not normalize vitamin D and K status in all subjects. Vitamin A levels did not exceed the normal range for any subject during the entire study period. Modest improvements in weight percentile and pulmonary function were observed. Change in plasma β-carotene concentrations weakly correlated with changes in weight and body mass index percentiles.


CONCLUSIONS
In this study, AquADEKs® increased systemic antioxidant levels, while maintaining vitamin A levels in the normal range, and improved but did not completely normalize vitamin D and K status. Increased β-carotene levels were associated with improved growth parameters. These results warrant further clinical evaluation in CF.
Department of Pediatrics, The Children's Hospital, University of Colorado Denver School of Medicine, Aurora, CO, USA. sagel.scott@tchden.org
Scott D
SD
Sagel
Marci K
MK
Sontag
Meg M
MM
Anthony
Peggy
P
Emmett
Konstantinos A
KA
Papas
D000293:Adolescent; D000975:Antioxidants / Q000378:metabolism / Q000627:therapeutic use; D054316:Biomarkers, Pharmacological; D015992:Body Mass Index; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D019587:Dietary Supplements / Q000009:adverse effects; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D010188:Exocrine Pancreatic Insufficiency / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D012129:Respiratory Function Tests; D016896:Treatment Outcome; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use; D014802:Vitamin A Deficiency / Q000097:blood / Q000209:etiology / Q000628:therapy*; D014808:Vitamin D Deficiency / Q000097:blood / Q000209:etiology / Q000628:therapy*; D014813:Vitamin K Deficiency / Q000097:blood / Q000209:etiology / Q000628:therapy*; D014815:Vitamins / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D055815:Young Adult
D000975:Antioxidants; D054316:Biomarkers, Pharmacological; D014815:Vitamins; D014451:Ubiquinone; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost; C024989:coenzyme Q10